Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × Vinorelbine × Clear all

NCT06690840 2026-01-05

AZALEA

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT02985658 2021-07-21

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

No longer available

Triple Negative Breast Neoplasms

NCT03932526 2019-04-30

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03358004 2018-10-05

VICTOR3

Phase 2 Terminated

Triple Negative Breast Neoplasms

NCT01104259 2017-08-10

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01528826 2012-02-08

NVBOX

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms